---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-007007"
form_type: "8-K"
ticker: "ISCO"
cik: "0001355790"
company_name: "International Stem Cell CORP"
filed_at: "2026-09-08T20:03:10+00:00"
generated_at: "2026-09-08T20:04:18.991584+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ISCO completes $25.25M sale of LCT to ATCC; pro forma shows higher continuing losses

## Summary
- Closed sale of Lifeline Cell Technology to ATCC on Sept 1, 2026; base price $25M + $250K add-back, adjusted to $25.688M.
- Net cash received at closing $21.688M; $2.6M escrow (working capital + indemnity) held as current asset.
- Estimated pre-tax gain on sale $22.174M; after-tax gain $19.316M; income tax payable $258K.
- Pro forma continuing net loss: $1.616M (H1 2026), $3.195M (FY2025), $3.199M (FY2024) vs smaller historical losses.
- Transaction costs $1.027M; intercompany payable of $9.445M from ISCO to LCT forgiven pre-close.

## SEC filing metadata
- accession: 0001683168-26-007007
- form_type: 8-K
- ticker: ISCO
- cik: 0001355790
- company_name: International Stem Cell CORP
- filed_at: 2026-09-08T20:03:10+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1355790/000168316826007007/0001683168-26-007007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1355790/000168316826007007/intlstemcell_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-007007
- JSON: https://secwatch.observer/filing/0001683168-26-007007.json
- Plain text: https://secwatch.observer/filing/0001683168-26-007007.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.
